MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
Rhea-AI Summary
MaxCyte (NASDAQ: MXCT) will release fourth quarter and full year 2025 financial results after U.S. market close on March 24, 2026. Management will host a conference call at 4:30 p.m. ET the same day to discuss results.
Investors must register online to join the call; a live and archived webcast will be available in the company’s Events section at the investor website.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
MXCT is up 0.93% while peers are mixed: LNSR up 3.18%, PROF up 0.58%, SGHT, ARAY, and RPID down. Only one momentum-screened peer (ELMD) shows a small downside move, suggesting stock-specific trading rather than a broad sector shift.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Prelim FY2025 results | Negative | -4.9% | Preliminary Q4 and FY2025 results described as challenging with guidance context. |
| Dec 01 | Executive move at peer | Neutral | -7.4% | Former MaxCyte commercial chief joining Cellares to support its IPO plans. |
| Nov 12 | CFO transition plan | Neutral | +1.9% | Planned CFO transition in 1H 2026 with assurances on continuity and strategy. |
| Nov 12 | Q3 2025 earnings | Negative | +1.9% | Q3 revenue decline and margin pressure while reiterating full‑year 2025 guidance. |
| Nov 05 | Prelim Q3 2025 | Positive | +3.7% | Preliminary Q3 2025 results with reiterated 2025 guidance and detailed cash levels. |
Recent news often saw negative or mixed items followed by modestly negative or positive moves, with several instances of price divergence from earnings-related announcements.
Over the past few months, MaxCyte has issued several earnings and corporate updates. Preliminary Q3 2025 results on Nov 5, 2025 and final Q3 earnings on Nov 12, 2025 reported revenue of $6.8M and reiterated full‑year guidance, yet shares moved between +1.94% and +3.73%. Preliminary Q4/FY 2025 results on Jan 12, 2026 highlighted a challenging year and led to a -4.9% move. Against this backdrop, today’s scheduling of the Mar 24, 2026 earnings release fits the ongoing earnings cadence without adding new financial details.
Market Pulse Summary
This announcement schedules MaxCyte’s fourth quarter and full‑year 2025 results for March 24, 2026, with a conference call at 4:30 p.m. Eastern Time. It follows preliminary Q4/FY 2025 data released on Jan 12, 2026. Investors monitoring the story may focus on how final audited figures compare with those preliminaries, any updates to revenue outlook for 2026, and management’s commentary on cost structure, cash position, and commercial traction.
AI-generated analysis. Not financial advice.
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2025 after the U.S. market close on Tuesday, March 24th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX® gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.
Investor Relations
Gilmartin Group
David Deuchler, CFA
ir@maxcyte.com
Media Relations
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com
FAQ
When will MaxCyte (MXCT) report Q4 and full year 2025 results?
What time is the MaxCyte (MXCT) earnings conference call on March 24, 2026?
How can investors listen to the MaxCyte (MXCT) Q4 2025 earnings call?
Will MaxCyte (MXCT) provide a webcast and archive for the March 24, 2026 call?
Is prior registration required to join the MaxCyte (MXCT) earnings call?
Where will MaxCyte (MXCT) post its Q4 and full year 2025 financial results and materials?
